RDHL Stock Overview
A specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RedHill Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.30 |
| 52 Week High | US$82.00 |
| 52 Week Low | US$6.43 |
| Beta | 3.67 |
| 11 Month Change | -1.55% |
| 3 Month Change | 0.37% |
| 1 Year Change | -51.81% |
| 33 Year Change | -99.79% |
| 5 Year Change | -99.87% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate
Sep 10
RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30RedHill Biopharma: Looking At An Unexciting Dead-End
Dec 30RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target
Dec 02Shareholder Returns
| RDHL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 20.4% | -2.7% | -3.4% |
| 1Y | -51.8% | 15.8% | 19.6% |
Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: RDHL underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| RDHL volatility | |
|---|---|
| RDHL Average Weekly Movement | 33.5% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RDHL's share price has been volatile over the past 3 months.
Volatility Over Time: RDHL's weekly volatility has decreased from 42% to 34% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 53 | Dror Ben-Asher | www.redhillbio.com |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
RedHill Biopharma Ltd. Fundamentals Summary
| RDHL fundamental statistics | |
|---|---|
| Market cap | US$13.19m |
| Earnings (TTM) | -US$30.17m |
| Revenue (TTM) | US$3.71m |
3.6x
P/S Ratio-0.4x
P/E RatioIs RDHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDHL income statement (TTM) | |
|---|---|
| Revenue | US$3.71m |
| Cost of Revenue | US$2.45m |
| Gross Profit | US$1.26m |
| Other Expenses | US$31.44m |
| Earnings | -US$30.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.56 |
| Gross Margin | 34.04% |
| Net Profit Margin | -813.97% |
| Debt/Equity Ratio | 0% |
How did RDHL perform over the long term?
See historical performance and comparison